Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Avista Public Acquisition Corp II Cl A
(NQ:
AHPA
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Nov 1, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
-
Bid (Size)
5.200 (10)
Ask (Size)
6.280 (1)
Prev. Close
6.125
Today's Range
N/A - N/A
52wk Range
N/A - N/A
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Why Pinterest Shares Jumped Around 14%; Here Are 69 Biggest Movers From Friday
October 31, 2022
Gainers Quanergy Systems, Inc. (NASDAQ: QNGY) jumped 153.9% to close at $3.30 on Friday.
Via
Benzinga
OmniAb Business Combination Approved by APAC Shareholders
October 24, 2022
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Performance
More News
Read More
Why Edwards Lifesciences Shares Are Trading Lower By Around 17%? Here Are 47 Stocks Moving In Friday's Mid-Day Session
October 28, 2022
Via
Benzinga
Janssen Scores Conditional Approval For Multiple Myeloma Treatment In Pretreated Patients
August 25, 2022
Via
Benzinga
Ligand Announces that Janssen has Received Approval from European Commission for TECVAYLI® (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
August 24, 2022
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Reports Second Quarter 2022 Financial Results
August 08, 2022
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Reports First Quarter 2022 Financial Results
May 04, 2022
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL
March 24, 2022
Via
Benzinga
Ligand To Spin-Off OmniAb Via Avista Capital-Backed SPAC Merger
March 24, 2022
Via
Benzinga
Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II
March 23, 2022
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
